2022 OMA临床实践声明:抗肥胖药物和研究药物

2022-08-02 肥胖医学协会 Obesity Pillars

2022年,肥胖医学协会(OMA)发布了抗肥胖药物和研究药物临床共识声明。本文主要介绍了FDA批准的抗肥胖药物和研究中的抗肥胖制剂。

中文标题:

2022 OMA临床实践声明:抗肥胖药物和研究药物

发布机构:

肥胖医学协会

发布日期:

2022-08-02

简要介绍:

2022年,肥胖医学协会(OMA)发布了抗肥胖药物和研究药物临床共识声明。本文主要介绍了FDA批准的抗肥胖药物和研究中的抗肥胖制剂。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 OMA临床实践声明:抗肥胖药物和研究药物.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4a46a1c002569a59, title=2022 OMA临床实践声明:抗肥胖药物和研究药物, enTitle=, guiderFrom=Obesity Pillars, authorId=0, author=, summary=2022年,肥胖医学协会(OMA)发布了抗肥胖药物和研究药物临床共识声明。本文主要介绍了FDA批准的抗肥胖药物和研究中的抗肥胖制剂。, cover=https://img.medsci.cn/20220805/1659662910754_5552845.jpg, journalId=0, articlesId=null, associationId=3050, associationName=肥胖医学协会, associationIntro=肥胖医学协会(OMA,Obesity Medicine Association), copyright=0, guiderPublishedTime=Tue Aug 02 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p>2022年,肥胖医学协会(OMA)发布了抗肥胖药物和研究药物临床共识声明。本文主要介绍了FDA批准的抗肥胖药物和研究中的抗肥胖制剂。</p>, tagList=[TagDto(tagId=457908, tagName=抗肥胖药物)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2116, appHits=39, showAppHits=0, pcHits=359, showPcHits=2075, likes=1, shares=3, comments=3, approvalStatus=1, publishedTime=Mon Aug 08 10:10:00 CST 2022, publishedTimeString=2022-08-02, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=dajiong, createdTime=Fri Aug 05 12:17:19 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Fri Jan 05 13:35:54 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 OMA临床实践声明:抗肥胖药物和研究药物.pdf)])
2022 OMA临床实践声明:抗肥胖药物和研究药物.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1237860, encodeId=2ccb123e86021, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a09e2550843, createdName=1254052em82(暂无昵称), createdTime=Wed Aug 10 16:32:11 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237391, encodeId=1689123e39109, content=肥胖的控制太重要了,糖尿病,高血压等代谢性疾病相关, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96198245009, createdName=ms3000001153881213, createdTime=Mon Aug 08 16:36:53 CST 2022, time=2022-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1237860, encodeId=2ccb123e86021, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a09e2550843, createdName=1254052em82(暂无昵称), createdTime=Wed Aug 10 16:32:11 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237391, encodeId=1689123e39109, content=肥胖的控制太重要了,糖尿病,高血压等代谢性疾病相关, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96198245009, createdName=ms3000001153881213, createdTime=Mon Aug 08 16:36:53 CST 2022, time=2022-08-08, status=1, ipAttribution=)]
    2022-08-08 ms3000001153881213

    肥胖的控制太重要了,糖尿病,高血压等代谢性疾病相关

    0